RU2007143928A - METHOD FOR PRODUCING A PHARMACEUTICAL PRODUCT FROM A CULTURAL ENVIRONMENT OF YEAST AND A PHARMACEUTICAL PRODUCT BASED ON A HUMAN ALPHA-INTERFERON (OPTIONS) - Google Patents
METHOD FOR PRODUCING A PHARMACEUTICAL PRODUCT FROM A CULTURAL ENVIRONMENT OF YEAST AND A PHARMACEUTICAL PRODUCT BASED ON A HUMAN ALPHA-INTERFERON (OPTIONS) Download PDFInfo
- Publication number
- RU2007143928A RU2007143928A RU2007143928/13A RU2007143928A RU2007143928A RU 2007143928 A RU2007143928 A RU 2007143928A RU 2007143928/13 A RU2007143928/13 A RU 2007143928/13A RU 2007143928 A RU2007143928 A RU 2007143928A RU 2007143928 A RU2007143928 A RU 2007143928A
- Authority
- RU
- Russia
- Prior art keywords
- interferon
- carried out
- ethylenediaminetetraacetic acid
- human alpha
- pharmaceutical preparation
- Prior art date
Links
Abstract
1. Способ получения фармацевтического препарата из культуральной среды дрожжей, включающий концентрирование культуральной среды, осаждение целевого белка и его хроматографическую очистку с использованием гель-фильтрации и ионообменной хроматографии, отличающийся тем, что культивируют штамм дрожжей Pichia pastoris, который является продуцентом альфа-16-интерферона человека, а хроматографическую очистку проводят последовательно на Сефакриле HR 100 и диэтиламиноэтил-целлюлозе. ! 2. Способ по п.1, отличающийся тем, что осаждение целевого белка проводят при 60%-ном насыщения сульфата аммония. ! 3. Способ по п.1, отличающийся тем, что гель-фильтрацию на Сефакриле HR 100 проводят с использованием в качестве уравновешивающего и элюирующего раствора 50 мМ аммоний-ацетатного буфера (рН 5,5), содержащего 2 мМ этилендиаминтетрауксусной кислоты и 0,5% Твин-20. ! 4. Способ по п.1, отличающийся тем, что ионообменную хроматографию белков, полученных по п.3, на диэтиламиноэтил-целлюлозе проводят с использованием в качестве уравновешивающего раствора 50 мМ аммоний-ацетатного буфера (рН 7,0), содержащего 2 мМ этилендиаминтетрауксусной кислоты, 0,5% Твин-20, а отмывку примесных белков осуществляют последовательным использованием уравновешивающего буферного раствора и уравновешивающего буферного раствора, содержащего 0,1 М хлористого натрия, элюцию проводят градиентом концентрации хлористого натрия 0,1-1,0 М в 50 мМ аммоний-ацетатном буфере (рН 5,5), содержащем 2 мМ этилендиаминтетрауксусной кислоты, 0,5% Твин-20. ! 5. Фармацевтический препарат на основе альфа-интерферона человека по первому варианту, содержащий этилендиаминтетрауксусную кислоту и солевую буферну1. A method of producing a pharmaceutical preparation from a yeast culture medium, comprising concentrating the culture medium, precipitating the target protein and chromatographic purification using gel filtration and ion exchange chromatography, characterized in that the strain of Pichia pastoris yeast, which is a producer of alpha-16 interferon, is cultivated human, and chromatographic purification is carried out sequentially on Sephacryl HR 100 and diethylaminoethyl cellulose. ! 2. The method according to claim 1, characterized in that the precipitation of the target protein is carried out at 60% saturation of ammonium sulfate. ! 3. The method according to claim 1, characterized in that gel filtration on Sephacryl HR 100 is carried out using 50 mM ammonium acetate buffer (pH 5.5) containing 2 mM ethylenediaminetetraacetic acid and 0.5 mm as a balancing and eluting solution. % Tween-20. ! 4. The method according to claim 1, characterized in that the ion-exchange chromatography of the proteins obtained according to claim 3 on diethylaminoethyl cellulose is carried out using 50 mM ammonium acetate buffer (pH 7.0) containing 2 mM ethylenediaminetetraacetic acid as a balancing solution. acid, 0.5% Tween-20, and the washing of impurity proteins is carried out sequentially using a balancing buffer solution and a balancing buffer solution containing 0.1 M sodium chloride, the elution is carried out by a concentration gradient of sodium chloride 0.1-1.0 M in 50 mM ammonium acetate buffer (pH 5.5) containing 2 mM ethylenediaminetetraacetic acid, 0.5% Tween-20. ! 5. The pharmaceutical preparation based on human alpha-interferon according to the first embodiment, containing ethylenediaminetetraacetic acid and saline buffer
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2007143928/13A RU2380405C2 (en) | 2007-11-29 | 2007-11-29 | Method for making recombinant human alpha 16-interferon and pharmaceutical composition for treating viral diseases based on recombinant human alpha 16-interferon |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2007143928/13A RU2380405C2 (en) | 2007-11-29 | 2007-11-29 | Method for making recombinant human alpha 16-interferon and pharmaceutical composition for treating viral diseases based on recombinant human alpha 16-interferon |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007143928A true RU2007143928A (en) | 2009-06-10 |
RU2380405C2 RU2380405C2 (en) | 2010-01-27 |
Family
ID=41024084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007143928/13A RU2380405C2 (en) | 2007-11-29 | 2007-11-29 | Method for making recombinant human alpha 16-interferon and pharmaceutical composition for treating viral diseases based on recombinant human alpha 16-interferon |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2380405C2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2557534C2 (en) * | 2013-12-06 | 2015-07-20 | Федеральное бюджетное учреждение науки научно-исследовательский институт Эпидемиологии Роспотребнадзора | Method for predicting antiviral treatment response in chronic hepatitis c |
-
2007
- 2007-11-29 RU RU2007143928/13A patent/RU2380405C2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2380405C2 (en) | 2010-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6593721B2 (en) | A chromatographic method to isolate and purify high-purity recombinant human serum albumin | |
US10414795B2 (en) | Techniques of preparing collagen active peptides | |
JP5948343B2 (en) | Method for purifying human serum albumin from seeds of transgenic rice | |
CN104710511B (en) | Iron chelating peptide derived from hairtail fish protein and preparation method and application thereof | |
CN109761833B (en) | A kind of isolation and purification method of L-Leu | |
JP2011525492A (en) | Purification of modified cytokines | |
CN105648008A (en) | Feeding silk antibacterial peptide preparation and preparation method thereof | |
CN101104635B (en) | Method for purifying recombination human alpha-whey albumin from transgene cow milk | |
EP0446582B1 (en) | Method for producing of recombinant human cysteineless gamma-interferon free of methionine at n-terminal | |
RU2007143928A (en) | METHOD FOR PRODUCING A PHARMACEUTICAL PRODUCT FROM A CULTURAL ENVIRONMENT OF YEAST AND A PHARMACEUTICAL PRODUCT BASED ON A HUMAN ALPHA-INTERFERON (OPTIONS) | |
CN105273076A (en) | Preparation method and pharmaceutical composition of PEGylated recombinant human granulocyte colony-stimulating factor | |
ES2370019T3 (en) | BETA INTERFERON PURIFICATION PROCEDURE. | |
FI74978B (en) | FRAMEWORK FOR FRAME STARTING OF MAENNIS-GAMMA-INTERFERON. | |
CN107058269A (en) | Medicinal kininogenase and its preparation method and application | |
ES2267201T3 (en) | RIBONUCLEOPOLIPTIDOS CONTAINING METAL. | |
ES2369911T3 (en) | BETA INTERFERON PURIFICATION PROCEDURE. | |
Khodwe et al. | Purification of arginine by ion-exchange chromatographic from cottonseed de-oiled cake | |
EP0248057B1 (en) | Glucose tolerance factor and method of making same | |
CN103923178B (en) | A kind of purposes of small peptide, its synthetic method and its enhancing domestic animal immunity | |
CN107011413A (en) | Tripeptides CGP with function of blood sugar reduction and application thereof | |
JPS6226226A (en) | Antitumor polypeptide | |
RU2722731C2 (en) | Method for producing biologically active components from yeast cells saccharomyces cerevisiae and a therapeutic agent based thereon | |
JPH01165393A (en) | Method for purifying recombinant human erytheropoietin | |
Denucé | Studies on experimental nephrosis in rats: I. Starch gel electrophoresis of serum and muscle proteins, including esterases | |
CN107236036A (en) | A kind of method of the factor of Prepare restructuring people blood coagulation eight |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Correction of name of patent owner | ||
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171130 |